“The first clinical study in Italy that investigates the connection between anti-Covid vaccination and thrombotic events” starts in Milan. It was led by the Monzino Cardiology Center (Ccm) and the State University of the Lombard capital, who announce the launch of the ‘Treasure’ project with the aim of “evaluating any variation in platelet activation, the mechanism at the origin thrombosis, induced by the administration of both mRna vaccines such as Pfizer and Moderna, and viral vector vaccines such as AstraZeneca and Johnson & Johnson “. Monzino and UniMi are looking for 200 Milanese interested in participating in the research, undergoing a simple blood test before and after vaccination. “Participate in the study” is the appeal launched by the IRCCS of the heart and by the university in via Festa del Perdono. “In addition to contributing to the collective knowledge on anti-Covid vaccines – they underline – the participants will enter a program to control their cardiovascular situation, which it is always good to monitor, especially in this pandemic period”. characterize the state of platelet activation before vaccination and evaluate any post-vaccine variation, also highlighting whether different types of shield product determine a different platelet activation. Treasure is aimed at the population aged 18 to 79, who must receive the first or second dose of Sars-Cov-2 vaccine. “The cases of thrombosis, although rare, following the administration of the AstraZeneca vaccine, have sown panic. But in reality there is no scientific proof of a causal link, nor that women are more at risk – says Marina Camera, professor at the University of Milan and head of the Cardiovascular Cell and Molecular Biology Unit of the CCM – For this reason, international scientific societies have recommended investigating the mechanisms of interaction between blood cells and vaccines. An invitation that we immediately accepted. The anti-Covid vaccination campaign will not end in 2021, but will accompany us for several years as central theme of public health “, underlines the expert, highlighting the importance of the experiment.” According to the recommendations issued by the European health authorities after a first examination and of the available data – Camera remembers – the most suspected are viral vector vaccines, so much so that in Italy they are reserved “preferentially” for over 60s, an age in which thrombotic events did not occur. The doubt remains that the reported cases, very few, compared to the millions of doses already administered in England and in the United States – points out the teacher – have nothing to do with the vaccine. Data in hand, in fact, their number is practically identical to the thrombosis affecting the unvaccinated population. For this, it is absolutely necessary to know more “. And it is essential” not to suspend or slow down the vaccination campaign: getting sick with Covid-19 – warns Camera – is much more dangerous than getting a vaccine. I therefore appeal to the Milanese to participate in our study and help research “.

https://connect.informs.org/network/members/profile?UserKey=61cee7f5-ceb6-4b9f-83f7-e55b33df1406
https://connect.informs.org/network/members/profile?UserKey=64220829-70bf-4641-873a-4d84f4e81f89
https://connect.informs.org/network/members/profile?UserKey=918c86f1-206e-4e84-ab30-eb51c18d74aa
https://connect.informs.org/network/members/profile?UserKey=d3e11175-f216-475e-b728-ed4e41dbb5a6
https://connect.informs.org/network/members/profile?UserKey=e05681ab-2fb1-449e-811e-2571e7e6785a
https://connect.informs.org/network/members/profile?UserKey=46f43f14-4a0a-4fec-bf33-6623e9fb53c1
https://connect.informs.org/network/members/profile?UserKey=4687bb49-ecc1-4ab5-9eb4-2c1b5d6410ef
https://connect.informs.org/network/members/profile?UserKey=02aca666-1aed-422a-ad58-92a56a87fec6
https://connect.informs.org/network/members/profile?UserKey=22334e6f-bf3a-442f-b1c7-c86ffa340e6e
https://connect.informs.org/network/members/profile?UserKey=53927e20-833d-495d-a946-38ba2ad60bb7
https://connect.informs.org/network/members/profile?UserKey=fa92a8df-a014-4229-ae87-0108d77b1d95
https://connect.informs.org/network/members/profile?UserKey=81e6ec98-ff06-45db-a327-2dd6af0adba2
https://connect.informs.org/network/members/profile?UserKey=62e71217-0b97-4503-bfd5-b052f4bbbff4
https://connect.informs.org/network/members/profile?UserKey=bd3977ee-ab4a-4c9a-8e8a-8c0eb9dd85c5
https://connect.informs.org/network/members/profile?UserKey=f68470e9-07c1-4709-9f09-515e41496d81
https://connect.informs.org/network/members/profile?UserKey=5128d00e-b5bb-433e-bcbd-50a82afd77d3
https://connect.informs.org/network/members/profile?UserKey=515660ae-8581-46f8-8207-3d56902f144d
https://connect.informs.org/network/members/profile?UserKey=f667189e-4a6b-48c0-a968-700250165eb9
https://connect.informs.org/network/members/profile?UserKey=c7f44216-078c-4a21-a42f-13a4a2d1fe17
https://connect.informs.org/network/members/profile?UserKey=1d9a1b08-6390-4546-885a-e8c2f5ce0692
https://connect.informs.org/network/members/profile?UserKey=f6deff43-516c-41a9-b337-3bb6d886c302
https://connect.informs.org/network/members/profile?UserKey=95881e57-7d79-4fc5-9a34-eedce4583fd9
https://connect.informs.org/network/members/profile?UserKey=2329288d-e00e-450f-bf37-438a1137ed38
https://connect.informs.org/network/members/profile?UserKey=feb9fb4c-7d92-4b12-8357-0e4dc663f885
https://connect.informs.org/network/members/profile?UserKey=a3791cfb-d2cc-498f-83c1-c194c946dc1e
https://connect.informs.org/network/members/profile?UserKey=931f5ca7-af09-4f1f-85a0-c9bf65b112b8
https://connect.informs.org/network/members/profile?UserKey=f1d8f378-2840-4004-91ed-58a54cb76dcf
https://connect.informs.org/network/members/profile?UserKey=96961728-280c-493c-acb3-569f2b863a28
https://connect.informs.org/network/members/profile?UserKey=5a370104-16cb-485c-8454-6fde425acc6b
https://connect.informs.org/network/members/profile?UserKey=59c67d91-4270-49e9-8994-fffb52b4abbe
https://connect.informs.org/network/members/profile?UserKey=3bbf3c1b-0706-4bd1-a750-e05390d9227d
https://connect.informs.org/network/members/profile?UserKey=c9a67f4d-e01f-4b2f-b30d-8870d930ea85
https://connect.informs.org/network/members/profile?UserKey=3751a370-cf50-4ffe-89db-546d6308561b
https://connect.informs.org/network/members/profile?UserKey=26dbd8bb-946d-4899-a813-46e9ce8b9d80
https://connect.informs.org/network/members/profile?UserKey=0e5bb4da-177b-4370-a749-06e25c235a96
https://connect.informs.org/network/members/profile?UserKey=a4d20b3d-f450-4b69-b8a6-84047c525af1
https://connect.informs.org/network/members/profile?UserKey=180033fb-affa-499e-aeba-0700c899345d
https://connect.informs.org/network/members/profile?UserKey=4437f4c1-4f9c-4d7a-abb7-c02f02c8ca74
https://connect.informs.org/network/members/profile?UserKey=c6071899-d985-464f-80d2-ff67e6aeb115
https://connect.informs.org/network/members/profile?UserKey=c0e16c97-c2ee-45a6-99b7-db01e39154a0
https://connect.informs.org/network/members/profile?UserKey=efbbb991-22e6-4a0e-bfd6-0c386264b22b
https://connect.informs.org/network/members/profile?UserKey=b9638fd2-eb6f-4617-a475-82bf58f20217
https://connect.informs.org/network/members/profile?UserKey=040242fd-267d-41f7-8635-6b8715722743
https://connect.informs.org/network/members/profile?UserKey=df869c17-9a54-49b2-8381-1fa60af46b51
https://connect.informs.org/network/members/profile?UserKey=6bc2850a-9913-4bf5-9bca-08be065381a6
https://connect.informs.org/network/members/profile?UserKey=5c33ce14-1c7e-419e-8e38-f02437b588ac
https://connect.informs.org/network/members/profile?UserKey=639a19f8-962c-4f19-8041-a74de67f6a7c
https://connect.informs.org/network/members/profile?UserKey=b46201b9-4f19-4fcd-b510-b0126338c2ce
https://connect.informs.org/network/members/profile?UserKey=f6076dfd-6302-4dbf-9ca9-fa423fc80eda
https://connect.informs.org/network/members/profile?UserKey=2d9e6c1a-7af5-47e0-b2df-bbd0660259a2